Technical Aspects for the Evaluation of Circulating Nucleic Acids (CNAs): Circulating Tumor DNA (ctDNA) and Circulating MicroRNAs

Castiglia, Marta; Pérez, Ainhoa Izquierdo; Serrano, María José; Ciaccio, Marcello; Bazan, Viviana; Russo, Antonio

doi:10.1007/978-3-319-55661-1_6

Cited by 2 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NGS allows the simultaneous analysis of multiple genes and samples, thereby reducing processing time and capital requirements. 108 Tagged-amplicon deep sequencing (TAm-Seq) technology can analyze multiple mutations from nearly 6000 bases in parallel to detect lowfrequency mutations in cfDNA. 78 Further development has spawned the InVision liquid biopsy platform, which uses enhanced TAm-Seq technology to identify low-frequency mutations in cfDNA.…”

Section: Ngsmentioning

confidence: 99%

“…The development of NGS has made cfDNA analysis more widely used. NGS allows the simultaneous analysis of multiple genes and samples, thereby reducing processing time and capital requirements 108 . Tagged‐amplicon deep sequencing (TAm‐Seq) technology can analyze multiple mutations from nearly 6000 bases in parallel to detect low‐frequency mutations in cfDNA 78 .…”

Section: Current Technologies For the Detection And Management Of Hemmentioning

confidence: 99%

See 1 more Smart Citation

Liquid biopsy technologies for hematological diseases

Zhang

Khoo

2020

Medicinal Research Reviews

View full text Add to dashboard Cite

Since the discovery of circulating tumor cells in 1869, technological advances in studying circulating biomarkers from patients' blood have made the diagnosis of nonhematologic cancers less invasive. Technological advances in the detection and analysis of biomarkers provide new opportunities for the characterization of other disease types. When compared with traditional biopsies, liquid biopsy markers, such as exfoliated bladder cancer cells, circulating cell‐free DNA (cfDNA), and extracellular vesicles (EV), are considered more convenient than conventional biopsies. Liquid biopsy markers undoubtedly have the potential to influence disease management and treatment dynamics. Our main focuses of this review will be the cell‐based, gene‐based, and protein‐based key liquid biopsy markers (including EV and cfDNA) in disease detection, and discuss the research progress of these biomarkers used in conjunction with liquid biopsy. First, we highlighted the key technologies that have been broadly adopted used in hematological diseases. Second, we introduced the latest technological developments for the specific detection of cardiovascular disease, leukemia, and coronavirus disease. Finally, we concluded with perspectives on these research areas, focusing on the role of microfluidic technology and artificial intelligence in point‐of‐care medical applications. We believe that the noninvasive capabilities of these technologies have great potential in the development of diagnostics and can influence treatment options, thereby advancing precision disease management.

show abstract

Section: Ngsmentioning

confidence: 99%

Section: Current Technologies For the Detection And Management Of Hemmentioning

confidence: 99%

Liquid biopsy technologies for hematological diseases

Zhang

Khoo

2020

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

Centrifugation-free extraction of circulating nucleic acids using immiscible liquid under vacuum pressure

Lee

Park

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Extraction of cell-free DNA (cfDNA), which exists at an extremely low concentration in plasma, is a critical process for either targeted-sensing or massive sequencing of DNAs. However, such small amount of DNA cannot be fully obtained without high-speed centrifugation (<20,000 g). Here, we developed a centrifugation-free cfDNA extraction method and system that utilizes an immiscible solvent under single low vacuum pressure throughout the entire process. It has been named Pressure and Immiscibility-Based EXtraction (PIBEX). The amounts of extracted cfDNA by PIBEX were compared with those extracted by the conventional gold standards such as QIAGEN using quantitative PCR (qPCR). The PIBEX system showed equal performance regarding extraction amount and efficiency compared to the existing method. Because the PIBEX eliminates the troublous and repetitive centrifugation processes in DNA extraction, it can be further utilized in microfluidic-sample preparation systems for circulating nucleic acids, which would lead to an integrated sample-to-answer system in liquid biopsies.

show abstract

Technical Aspects for the Evaluation of Circulating Nucleic Acids (CNAs): Circulating Tumor DNA (ctDNA) and Circulating MicroRNAs

Cited by 2 publications

References 39 publications

Liquid biopsy technologies for hematological diseases

Liquid biopsy technologies for hematological diseases

Centrifugation-free extraction of circulating nucleic acids using immiscible liquid under vacuum pressure

Contact Info

Product

Resources

About